ATMP Market Access: ensuring sustainable patient access to life-changing therapies
Advanced Therapy Medicinal Products (ATMPs) include cell therapies, gene therapies and tissue engineered products. These regenerative therapies aim to alter the current treatment paradigms by targeting the cause of diseases and disorders. Successful adoption of ATMPs, with potentially curative effects after one treatment cycle, can provide significant clinical and economic benefits to multiple stakeholders.
As of Q3 2020 there were 97 on-going phase III clinical trials of ATMPs globally and with continued investment in the sector (public, private and corporate), all stakeholders must engage in conversation now to ensure timely patient access to these innovative, potentially curative, medicines.
Challenges related to HTA methods for evaluating ATMPs and achieving sustainable market access
There is no “one size fits all” approach to fit the requirements of all health systems, the correct strategy will depend on the individual healthcare system, the indication in question and the data available at launch. A broad understanding of the landscape is vital to ensure timely patient access. Effective strategies to ensure a successful launch may include mapping stakeholder needs (payer, HCP, patient), establishing early dialogue with payers and collaboration (inter-industry and between manufacturers and payers) to provide innovative payment/financial solutions for sustainable access to high-cost, potentially curative, therapies.
How can we support you to navigate your access challenges associated with ATMPs?
Lightning Health has an extensive stakeholder network (including industry representatives, payers, KOLs and HCPs), with experience across clinical development, pricing & market access, and value communication for ATMPs. Our expert team, at the forefront of thought leadership, promoting sustainable and equitable patient access to ATMPs, can support you throughout the life-cycle of your advanced therapy. To read more about our current thought-leadership perspective click here.
Who we are
We are a team of highly experienced market access professionals and leading industry and policy stakeholders from around the world. Our experience spans industry, government and strategic consultancy. We are digitally led, solution oriented and support optimal patient access and uptake across healthcare systems. We take pride in building dynamic, collaborative partnerships that provide a true extension to your team.
Eleanor Butler, Market Access Consultant, has a history of providing strategic expertise to clients developing cell and gene therapies including therapy area pipeline analysis, pricing and market access strategy development, assessing the potential for innovative payment/financial models, and brand planning for products in latestage development.
Eleanor’s specialist research area, on mitigating the challenges associated with patient access to innovative new ATMPs, is ongoing and a recent thought-leadership piece, harnessing the opinions of global expert payers was presented at ISPOR Europe 2020.
The API Platform
The API Platform provides on-demand insights from our global network of payer and physician stakeholders on average within 5-10 working days. The technology can be used as a standalone tool or to optimise consultancy projects.
Contact us
Our expert team and extensive stakeholder network can support you through the life cycle of your advanced therapy. Get in touch to discuss how Lightning Health can partner with you for your market access strategy.
enquiries@lightning-api.com ebutler@lightning-api.com
www.lightning-api.com +44(0) 203 488 3983
Follow us on LinkedIn
RCT: Randomised Clinical Trial; HCP: Healthcare Professional; HTA: Health Technology Assessment; KOL: Key Opinion Leader; RWD: Real World Data; TPP: Target Product Profile
Article published 10 March 2021.
In this article, our colleagues Eleanor Butler and Nancy Cross carry out a retrospective review of the NICE CAR-T therapy single technology appraisals
Nasos Kipentzoglou, Analyst and Eleanor Butler, Consultant at Lightning Health review the recent approach that the G-BA has taken in requiring the mandatory collection of real world evidence for Zolgensma®
Following NICE draft guidance rejecting Zynteglo, Eleanor Butler, Consultant at Lightning Health explores why the beta thalassaemia treatment is not recommend for routine NHS funding
